Experts say the FDA’s decision might make hormonal therapies more accessible to people with menopausal symptoms, which include hot flashes and night sweats. After the FDA added warning labels in 2003, research showed that the risks of cancer and metabolic disease were overstated and that this may have deterred both hormone therapy users and providers. But experts also caution that FDA’s new announcement, in turn, exaggerated the therapies’ benefits for other conditions.